Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Managing diabetes in patients with diabetes of long duration.

Triplitt CL.

Diabetes Educ. 2012 Jul-Aug;38(4 Suppl):23S-30S; quiz 31S. doi: 10.1177/0145721712449390. Epub 2012 Jun 1. Review.

PMID:
22661393
2.

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, Verhoeven R, Bugánová I, Madsbad S.

Diabetes Care. 2007 Jun;30(6):1608-10. Epub 2007 Mar 19. No abstract available.

PMID:
17372153
3.

Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes.

Blevins T.

Postgrad Med. 2010 Jan;122(1):172-83. doi: 10.3810/pgm.2010.01.2111. Review.

PMID:
20107301
4.
5.
6.

Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia.

Shogbon AO, Levy SB.

Am J Health Syst Pharm. 2010 May 15;67(10):798-805. doi: 10.2146/ajhp090211. Review.

PMID:
20479101
7.

The effects of improved glycemic control on complications in type 2 diabetes.

Gaster B, Hirsch IB.

Arch Intern Med. 1998 Jan 26;158(2):134-40. Review.

PMID:
9448551
8.

[New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].

[No authors listed]

MMW Fortschr Med. 2010 Oct 7;152(40):44-5. German. No abstract available.

PMID:
21049644
9.
10.

Managing loss of glycemic control in middle-aged patients with diabetes: the role of GLP-1 receptor agonists in combination-therapy regimens.

Repas TB.

J Am Osteopath Assoc. 2014 May;114(5 Suppl 2):S14-21. doi: 10.7556/jaoa.2014.085. Review.

PMID:
24769504
11.

Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.

Tzefos M, Olin JL.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1294-300. doi: 10.1345/aph.1P047. Epub 2010 Jun 8. Review.

PMID:
20530705
12.

Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.

Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S.

Ann Intern Med. 2011 Apr 19;154(8):554-9. doi: 10.7326/0003-4819-154-8-201104190-00007. Review.

PMID:
21502652
13.

[Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].

[No authors listed]

MMW Fortschr Med. 2012 Feb 23;154(3):82-3. German. No abstract available.

PMID:
22458177
14.
15.

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.

Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS.

Diabetes Care. 1995 Aug;18(8):1113-23.

PMID:
7587846
16.
17.

Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.

Bode BW, Brett J, Falahati A, Pratley RE.

Am J Geriatr Pharmacother. 2011 Dec;9(6):423-33. doi: 10.1016/j.amjopharm.2011.09.007. Epub 2011 Nov 4.

PMID:
22055210
18.

Optimizing outcomes for GLP-1 agonists.

Freeman JS.

J Am Osteopath Assoc. 2011 Feb;111(2 Suppl 1):eS15-20. Review.

PMID:
21389295
19.

GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.

Holst JJ, Seino Y.

Diabetes Res Clin Pract. 2009 Jul;85(1):1-3. doi: 10.1016/j.diabres.2009.02.017. Epub 2009 Mar 18. No abstract available.

PMID:
19299027
20.

Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review.

Germino FW.

Clin Ther. 2011 Dec;33(12):1868-82. doi: 10.1016/j.clinthera.2011.10.020. Epub 2011 Dec 2. Review.

PMID:
22136979

Supplemental Content

Support Center